Vanguard Capital Management
APGE icon

Vanguard Capital Management’s Apogee Therapeutics APGE Stock Holding History

Vanguard Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$341M Buy
2,572,119
+70,024
+3% +$6.31M 0.01% 848
2026
Q1 		$211M Buy
+2,502,095
New +$182M 0.01% 1034

Other funds holding APGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's APGE Position: Q2 2026 in Review

Vanguard Capital Management increased its Apogee Therapeutics (APGE) stake by 2.8% in Q2 2026, buying an estimated $6.31M and bringing the position to 2,572,119 shares worth $341M. The position accounts for 0.01% of the portfolio, ranked #848.

Vanguard Capital Management first reported a position in APGE in Q1 2026 and has held it in 2 quarters since. 258 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Vanguard Capital Management held 2,572,119 shares of Apogee Therapeutics worth $341M as of Q2 2026.
  • Vanguard Capital Management bought 70,024 Apogee Therapeutics shares in Q2 2026, an estimated $6.31M.
  • Apogee Therapeutics made up 0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #848 holding.
  • Vanguard Capital Management first reported a position in Apogee Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 258 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.